Axio BioPharma Awarded for AI-Ready Manufacturing
Axio BioPharma has been named an ICP Round 1 awardee for its efforts to advance "AI-ready" biologics manufacturing in Wisconsin. The company is focusing on embedding digital tools and machine learning algorithms directly into its process development and quality assurance workflows. This approach aims to use autonomous systems for routine optimization, freeing scientists for higher-level work.
- The Innovation to Commercialization Pipeline (ICP) program is a Wisconsin-based initiative by Forward BIOLABS and BioForward Wisconsin, providing $25,000 to $75,000 in non-dilutive funding to early-stage biohealth companies. It is supported by state-matched funds from the Wisconsin Biohealth Tech Hub, which aims to help startups overcome commercialization challenges and secure further investment. - Axio BioPharma was one of 18 companies selected for the first ICP round, a cohort that also included startups in radiopharmaceuticals (Archeus Technologies), pediatric rare skin diseases (Arkayli Biopharma), and noninvasive respiratory sensors (AyrFlo Innovation Labs). - The "AI-ready" approach is a core component of Pharma 4.0, which applies Industry 4.0 principles to biomanufacturing by creating interconnected, data-driven operations. This framework uses AI, IoT, and cloud computing to create dynamic, self-optimizing systems that enhance process control and ensure GMP compliance. - A key application of AI in this context is the creation of digital twins, which are virtual models of a bioprocess used to simulate and optimize manufacturing without extensive physical experiments. For example, Merck has used digital twins to run *in silico* Design of Experiments (DOE) for continuous manufacturing, reducing the timeline and material costs for process development. - Foundational to AI-driven manufacturing is the shift from paper to Electronic Batch Records (EBRs), as a single cell and gene therapy batch can generate upwards of 3,000 distinct data points. EBR systems are essential for ensuring data integrity under regulations like 21 CFR Part 11 and creating the structured datasets that machine learning models require. - This data-centric approach is critical for tackling challenges in complex biologics like viral vectors, where manufacturing processes are not standardized, unlike monoclonal antibodies. Significant variability exists in analytical methods for viral vectors, such as measuring full-to-total capsid ratios, which complicates process optimization and regulatory filings. - Madison-based Axio BioPharma was founded in 2024 by CEO Justin Byers with the goal of reducing monoclonal antibody development timelines from years to just days. The company launched its initial protein manufacturing services in September 2024 and aims to provide GMP manufacturing by early 2028. - The ICP award reflects a broader strategy to expand Wisconsin's biohealth industry, anchored by the Wisconsin Biohealth Tech Hub, which is set to receive nearly $50 million in federal funding to accelerate company growth and innovation.
